The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors: A UNICANCER phase I study.
Veronique Dieras
Honoraria - GlaxoSmithKline
Thomas Bachelot
No relevant relationships to disclose
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Nicolas Isambert
No relevant relationships to disclose
Florence Joly
Honoraria - GlaxoSmithKline
Christophe Le Tourneau
No relevant relationships to disclose
Philippe Alexandre Cassier
Consultant or Advisory Role - SERVIER
Honoraria - GlaxoSmithKline; Novartis
Research Funding - Novartis; Roche
Other Remuneration - Novartis; SERVIER
Emmanuelle Bompas
No relevant relationships to disclose
Pierre Fumoleau
No relevant relationships to disclose
Sabine Noal
No relevant relationships to disclose
Christine Orsini
No relevant relationships to disclose
Marta Jimenez
No relevant relationships to disclose
Diane Charlotte Imbs
No relevant relationships to disclose
Etienne Chatelut
No relevant relationships to disclose